Patent US5077276A successfully refreshed from Google Patents.
US5077276A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Growth factor
Assignee: BRESATEC Ltd
•
Filing: 1986-08-21
•
Granted: 1991-12-31
•
Expires: 2006-08-21
Abstract
Abstract A peptide analogue of mammalian insulin-like growth factor-1 wherein from 1 to 5 amino acid residues are absent from the N-terminal.
Inventors
- 👤 Francis J. Ballard
- 👤 John C. Wallace
- 👤 Geoffrey L. Francis
- 👤 Christopher J. Bagley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/65; A; A61; A61P; A61P29/00; A61P35/00; A61P43/00; A61K; A61K38/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
21 words
A peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.
Claim 2
Dependent Claim
21 words
A peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.
Claim 3
Dependent Claim
12 words
A peptide analogue according to claim 1 in a biologically pure form.
Claim 4
Dependent Claim
56 words
A pharmaceutical or vertinary composition for the treatment of protein accumulation deficiencies or protein loss in mammals including: (a) an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly; and (b) a pharmaceutically or venterinarilly acceptable diluent, carrier or excipient therefor.
Claim 5
Dependent Claim
56 words
A pharmaceutical or vertinary composition for the treatment of protein accumulation deficiencies or protein loss in mammals including: (a) an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly; and (b) a pharmaceutically or venterinarilly acceptable diluent, carrier or excipient therefor.
Claim 6
Dependent Claim
21 words
A composition according to claim 3 wherein the peptide analogue is present in amounts of from approximately 0.02 to 2000 milligrams.
Claim 7
Independent Claim
46 words
A method for the treatment of protein accumulation deficiencies in mammals which method includes administering to a mammal to be treated an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.
Claim 8
Independent Claim
46 words
A method for the treatment of protein accumulation deficiencies in mammals which method includes administering to a mammal to be treated an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-tyr-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.
Claim 9
Dependent Claim
35 words
A method according to claim 5 wherein the protein accumulation deficiencies to be treated are those which are associated with cancer, cystic fibrosis, Duchenne muscular dystrophy, Becker dystrophy, autosomal recessive dystrophy, polymyositis, or other myophathies.
Claim 10
Dependent Claim
23 words
A method according to claim 5 wherein the peptide analogue is administered at a dose rate of approximately 1 to 1000 microgram/kg bodyweight/day.
Claim 11
Independent Claim
45 words
A method for the treatment of protein loss in mammals which method includes administering to a mammal to be treated an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-try-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.
Claim 12
Independent Claim
45 words
A method for the treatment of protein loss in mammals which method includes administering to a mammal to be treated an effective amount of a peptide analogue of bovine or human insulin-like growth factor-1 having the structure: X-try-gly-ser-ser-ser-arg-arg-ala-pro-gln-thr-gly-ile-val-asp-glu-cys-cys-phe-arg-ser-cys-asp-leu-arg-arg-leu-glu-met-tyr-cys-ala-pro-leu-lys-pro-ala-lys-ser-ala wherein X is the N-terminal structure: Thr-leu-cys-gly-ala-glu-leu-val-asp-ala-leu-gln-phe-val-cys-gly-asp-arg-gly-phe-tyr-phe-asn-lys-pro-thr-gly.
Claim 13
Dependent Claim
18 words
A method according to claim 8 wherein the protein loss is related to burns, skeletal trauma or infection.
Claim 14
Dependent Claim
23 words
A method according to claim 8 wherein the peptide analogue is administered at a dose rate of approximately 1 to 1000 microgram/kg bodyweight/day.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-30 | 1995-07-01 | 1995-12-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-30 | 1999-07-01 | 1999-12-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-30 | 2003-07-01 | 2003-12-31 | $7700.00 | Window Closed / Lapsed |